9.485

7.01% -0.715

After Hours: 9.49 0.005 +0.05%

Arcturus Therapeutics Holdings Inc (ARCT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arcturus Therapeutics Holdings Inc stock is traded at $9.485, with a volume of 362.42K. It is down -7.01% in the last 24 hours and down -39.51% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Previous Close:

$10.20

Open:

$9.59

24h Volume:

362.42K

Relative Volume:

0.90

Market Cap:

$257.23M

Revenue:

$157.75M

Net Income/Loss:

$-29.73M

P/E Ratio:

-8.1767

EPS:

-1.16

Net Cash Flow:

$-21.00M

1W Performance:

-20.96%

1M Performance:

-39.51%

6M Performance:

-61.69%

1Y Performance:

-71.03%

1-Day Range:

$9.18

$9.80

1-Week Range:

$9.18

$12.10

52-Week Range:

$9.18

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name

Arcturus Therapeutics Holdings Inc

Sector

Healthcare (1182)

Industry

Biotechnology (678)

Phone

(858) 900-2660

Address

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

176

Twitter

@ArcturusRx

Next Earnings Date

2024-11-07

Latest SEC Filings

ARCT's Discussions on Twitter

Compare ARCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARCT Arcturus Therapeutics Holdings Inc	9.485	257.23M	157.75M	-29.73M	-21.00M	-1.16
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	BTIG Research	Buy
Aug-12-24	Initiated	Leerink Partners	Outperform
Dec-13-23	Initiated	Canaccord Genuity	Buy
Jul-24-23	Initiated	William Blair	Outperform
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-14-22	Resumed	Wells Fargo	Overweight
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform
Nov-03-22	Upgrade	Citigroup	Neutral → Buy
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral
Apr-21-22	Downgrade	Citigroup	Buy → Neutral
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-25-21	Resumed	Goldman	Neutral
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell
Jan-19-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-15-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-07-21	Initiated	Wells Fargo	Overweight
Dec-29-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-29-20	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-29-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-23-20	Downgrade	ROTH Capital	Buy → Sell
Dec-08-20	Reiterated	B. Riley Securities	Buy
Dec-07-20	Reiterated	B. Riley Securities	Buy
Oct-26-20	Initiated	Barclays	Overweight
Oct-06-20	Initiated	Citigroup	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-30-20	Resumed	ROTH Capital	Buy
Jul-16-20	Initiated	Raymond James	Outperform
Jul-13-20	Initiated	B. Riley FBR	Buy
Jun-09-20	Downgrade	WBB Securities	Buy → Hold
Feb-11-20	Initiated	Robert W. Baird	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Apr-05-19	Initiated	H.C. Wainwright	Buy
Sep-20-18	Upgrade	WBB Securities	Buy → Strong Buy
Jan-22-18	Initiated	Chardan Capital Markets	Buy

View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025

Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025

Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025

Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025

Mar 17, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - Markets Insider

Mar 12, 2025

Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025

Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025

Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025